Product Description
Latanoprostene bunod ophthalmic solution 0.024% (hereafter referred to as latanoprostene bunod 0.024%) [Vyzulta™] is a nitric oxide (NO)-donating prostaglandin F2alpha analogue approved in the USA for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29761382/)
Mechanisms of Action: PGF Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Brazil | Canada | Colombia | Hong Kong | Jordan | Korea | Lebanon | Mexico | Singapore | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United States
Approved Indications: Hypertension | Glaucoma | Glaucoma, Open-Angle
Known Adverse Events: Hyperemia | Eye Pain | Pain Unspecified
Company: Bausch & Lomb
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypertension|Glaucoma, Open-Angle
Phase 3: Glaucoma|Hypertension|Glaucoma, Open-Angle
Phase 2: Hypertension|Glaucoma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT04140279 | P4 |
Withdrawn |
Hypertension |
2023-08-01 |
|
| NCT03931317 | N/A |
Completed |
Hypertension|Glaucoma, Open-Angle |
2021-05-20 |
|
| GCO 18-2686 | P4 |
Completed |
Glaucoma, Open-Angle |
2020-10-01 |
|
| Apollo study | P3 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2015-06-02 |